Multitracer PET/CT with [18F]Fluorodeoxiglucose and [18F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study
暂无分享,去创建一个
R. D. Delgado Bolton | X. B. Boulvard Chollet | L. R. Romero Robles | R. Ramírez Lasanta | M. Mangas Losada | Alejandro Mendoza Melero | I. García Megías | Amós Villanueva Torres | P. Garrastachu Zumarán | Prisma Montserrat Hernández Pérez
[1] S. Fanti,et al. Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors With the Clinical Application of FAPI Imaging? , 2023, Clinical nuclear medicine.
[2] S. Fanti,et al. The Concept of Strength Through Synergy Applied to the Search of Powerful Prognostic Biomarkers in Gastroesophageal Cancer: An Example Based on Combining Clinicopathological Parameters, Imaging-Derived Sarcopenia Measurements, and Radiomic Features. , 2022, Clinical nuclear medicine.
[3] A. Alavi,et al. 18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma. , 2022, PET clinics.
[4] S. Fanti,et al. New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms: The Light Leading Out of the Darkness in Challenging Tumors. , 2022, Clinical nuclear medicine.
[5] H. Goldschmidt,et al. The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs) , 2021, EJNMMI Research.
[6] D. Rubello,et al. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma , 2021, Clinical nuclear medicine.
[7] G. Martinelli,et al. PET/CT in Multiple Myeloma: Beyond FDG , 2021, Frontiers in Oncology.
[8] E. Hindié,et al. Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial , 2020, JMIR research protocols.
[9] E. Hindié,et al. Choline PET/CT in Multiple Myeloma , 2020, Cancers.
[10] Gary A Ulaner,et al. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. , 2020, Radiology.
[11] A. Buck,et al. 18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers , 2020, Cancers.
[12] Alberto Costa,et al. ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. , 2020, Critical reviews in oncology/hematology.
[13] H. Goldschmidt,et al. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma , 2019, Molecules.
[14] W. Oyen,et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[15] H. Goldschmidt,et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. , 2019, The Lancet. Oncology.
[16] S. Samnick,et al. Comparison of 11C-Choline and 11C-Methionine-PET/CT in Multiple Myeloma , 2019, Nuklearmedizin.
[17] A. Rosenwald,et al. Hexokinase-2 Expression in 11C-Methionine–Positive, 18F-FDG–Negative Multiple Myeloma , 2018, The Journal of Nuclear Medicine.
[18] I. Špička,et al. Is fluorine-18-fluorocholine PET/CT suitable for the detection of skeletal involvement of multiple myeloma? , 2018, Hellenic journal of nuclear medicine.
[19] C. Nanni,et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[20] C. Cicciò,et al. PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. , 2017, Nuclear medicine and biology.
[21] Caleb K. Stein,et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.
[22] Bart Barlogie,et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.
[23] M. Mohty,et al. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Michael Lassmann,et al. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease , 2016, The Journal of Nuclear Medicine.
[25] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[26] Hans Erik Johnsen,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.
[27] A. Massaro,et al. New Acquisition Protocol of 18F-Choline PET/CT in Prostate Cancer Patients: Review of the Literature about Methodology and Proposal of Standardization , 2014, BioMed research international.
[28] Sirong Chen,et al. 11C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with 18F-FDG PET/CT , 2014, The Journal of Nuclear Medicine.
[29] R. Boellaard,et al. Optimized dose regimen for whole-body FDG-PET imaging , 2013, EJNMMI Research.
[30] K. Togashi,et al. Clinical value of 11C-methionine PET/CT in patients with plasma cell malignancy: comparison with 18F-FDG PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[31] B. Barlogie,et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.
[32] Ji-An Liang,et al. FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma: A Systematic Review and Meta-analysis , 2012, Clinical nuclear medicine.
[33] Virginie Huchet,et al. Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of 18F-Fluorocholine and 18F-FDG in Patients with Cirrhosis or Chronic Liver Disease , 2010, The Journal of Nuclear Medicine.
[34] Orazio Schillaci,et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer , 2010, Nuclear medicine communications.
[35] Wim J. G. Oyen,et al. Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma , 2009, Annals of Hematology.
[36] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[37] V. Ambrosini,et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma , 2007, World journal of surgical oncology.
[38] V. Ambrosini,et al. Incidental finding of an 11C-choline PET-positive solitary plasmacytoma lesion , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[39] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[40] Hyun Woo Kwon,et al. Incidental finding of an 11C-acetate PET-positive multiple myeloma , 2010, Annals of nuclear medicine.